Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May 1;70(6):584-90.
doi: 10.1002/pros.21092.

Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial

Alan R Kristal  1 , Douglas K Price, Cathee Till, Jeannette M Schenk, Marian L Neuhouser, Sandy Ockers, Daniel W Lin, Ian M Thompson, William D Figg
Affiliations

Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial

Alan R Kristal et al. Prostate. .

Abstract

Background: To examine whether androgen receptor (AR) CAG repeat length was associated with the risk of incident benign prostatic hyperplasia (BPH).

Methods: A nested case-control study of 416 BPH cases and 527 controls drawn from Prostate Cancer Prevention Trial placebo-arm participants who were free of BPH at baseline. BPH was assessed over 7 years and was defined as receipt of medical or surgical treatment, two scores > 14 on the International Prostate Symptom Score (IPSS), or two increases in IPSS > or = 5 with at least one score > or = 12.

Results: Compared to men with AR repeat length < or = 19, the covariate-adjusted odds ratios [95% CI] were 1.07 [0.73, 1.57] and 0.90 [0.55, 1.45]) for repeat length 20-24 and > or =25, respectively. There was a weak association of AR repeat length with baseline serum testosterone (T) (Spearman r = 0.09, p < 0.02); however, control for or stratification by T did not change study results. Further, results did not differ when stratified by body mass index or baseline concentration of 3alpha-diol glucoronide, and were similar for all BPH definitions.

Conclusions: There were no associations of AR CAG repeat length and BPH risk. Knowledge of AR CAG repeat length provides no clinical useful information for the prevention of symptomatic BPH.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Kirby RS. The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology. 2000;56:3–6. - PubMed
    1. Platz EA, Smit E, Curhan GC, Nyberg LM, Giovannucci EL. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men. Urology. 2002;59:877–883. - PubMed
    1. Moore CR. Physiology of the testes and therapeutic applicationof male hormone. Bull N Y Acad Med. 1940;16(3):135–152. - PMC - PubMed
    1. Kristal AR, Schenk JM, Song YJ, Arnold KB, Neuhouser ML, Goodman PJ, Lin D, Stanczyk F, Thompson IM. Serum steroid and sex hormone binding globulin concentrations and the risk of incident benign prostatic hyperplasia (BPH): Results from the Prostate Cancer Prevention Trial. Am J Epidemiol. 2008;168:1416–1424. - PMC - PubMed
    1. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Rayan A, Szczepanek CM, Crowley JJ, Coltman CA. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224. - PubMed